US Capitol Capsule: Drive, faith and some government help: building biotech success
This article was originally published in Scrip
While there's 100 or so biotechs formed each year, an extraordinary thing happened last week that not only was another sign the industry is thriving after years of struggle, but also was a major achievement for the US National Center for Advancing Translational Sciences (NCATS), whose mission includes de-risking investigational medicines to attract commercial investment, with the aim of getting those products to the market sooner.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.